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PU.1 is essential for early stages of mouse T cell development but
antagonizes it if expressed constitutively. Two separable mecha-
nisms are involved: attenuation and diversion. Dysregulated PU.1
expression inhibits pro-T cell survival, proliferation, and passage
through -selection by blocking essential T cell transcription fac-
tors, signaling molecules, and Rag gene expression, which expres-
sion of a rearranged T cell antigen receptor transgene cannot
rescue. However, Bcl2 transgenic cells are protected from this
attenuation and may even undergo -selection, as shown by PU.1
transduction of defined subsets of Bcl2 transgenic fetal thymocytes
with differentiation in OP9-DL1 and OP9 control cultures. The
outcome of PU.1 expression in these cells depends on NotchDelta
signaling. PU.1 can efficiently divert thymocytes toward a myeloid-
like state with multigene regulatory changes, but NotchDelta
signaling vetoes diversion. Gene expression analysis distinguishes
sets of critical T lineage regulatory genes with different combina-
torial responses to PU.1 and NotchDelta signals, suggesting par-
ticular importance for inhibition of E proteins, Myb, andor Gfi1
(growth factor independence 1) in diversion. However, Notch
signaling only protects against diversion of cells that have under-
gone T lineage specification after Thy-1 and CD25 up-regulation.
The results imply that in T cell precursors, NotchDelta signaling
normally acts to modulate and channel PU.1 transcriptional
activities during the stages from T lineage specification until
commitment.
gene regulation  hematopoiesis  lineage commitment 
T cell development  transcription factors
T lymphocyte lineage determination is a remarkably protractedprocess. After T cell precursors segregate from other hemato-
poietic precursors bymigrating to the thymus, aftermultiple rounds
of cell division within the thymus, and even after initiating a T
lineage gene expression program, the cells still preserve access to
seemingly very different fates, such as myeloid cell differentiation
(reviewed in refs. 1–3). The positive regulatory events that initiate
the T cell differentiation program in vivo are temporally and
mechanistically distinct from the regulatory mechanisms that make
it irreversible. A possible basis for the delay in T lineage commit-
ment is that the early stages of T cell development depend on
factors such as theEts-family transcription factor PU.1 (4–7), which
is also an activator of myelomonocytic differentiation (8, 9). Nor-
mal, essential roles of PU.1 in early T cells may come at a cost of
developmental instability.
Gene expression and functional perturbation data suggest that
PU.1 down-regulation may normally be rate limiting for T lineage
commitment in vivo. The earliest stage intrathymic precursors,
double-negative (DN) 1 (Thy-1low c-kit2 CD44 CD25), express
high levels of PU.1 (2, 10, 11) and havemultilineage developmental
potential. Potential to give rise to natural killer cells, dendritic cells,
and macrophages persists through the DN2 (Thy-1 c-kit CD44
CD25) stage, along with lower but continuing PU.1 expression.
Commitment, the loss of these last alternative developmental
potentials, occurs at the DN3 (Thy-1 c-kit CD44 CD25) stage
as the cells stop dividing and undergoT cell antigen receptor (TCR)
gene rearrangement.Only cells successful in TCR- rearrangement
then continue development and pass through -selection. They
down-regulate CD25 (DN4 stage) and express cell-surface CD4,
CD8, and TCR, finally becoming double-positive (DP) cells (sum-
marized in Fig. 1C). An alternative pathway from DN3 leads to
development of TCR- T cells (12). Commitment at the DN3
stage coincides with an100-times drop in the expression of PU.1
RNA (2, 12).
Lymphoid precursors can be diverted into other hematopoietic
lineages by ectopic expression of transcription factors or ectopic
cytokine receptor stimulation (for example, refs. 13–15; reviewed in
ref. 3). Similarly, forced high-level expression of PU.1 can redirect
T cell precursors to amyeloid-like or dendritic cell fate (16, 17). But
PU.1 is not ectopic to T lineage differentiation: instead, until
commitment, it is essential. If PU.1 shutoff explains loss of myeloid
potential at the DN3 stage, the question remains how precursors
that normally express high levels of PU.1 ever arrive at that stage.
It follows that under normal circumstances, the T lineage differ-
entiation program leading up to commitment must also include
regulatory constraints that channel PU.1 effects to exclude alter-
native developmental outcomes.
This report shows that the pro-T cell development program
indeed incorporates such constraints on PU.1 activity. Notably,
these constraints are not cell autonomous, as is Pax-5 in B cell
specification (18); rather, they depend on environmental signaling.
We show that once T lineage differentiation initiates, NotchDelta
signaling selectively restricts the actions of PU.1.
Results
Pro-T Cells Forced to Express PU.1 Cannot Be Rescued by a TCR
Transgene. Forced expression of PU.1 from a bicistronic retroviral
vector in developing T cell precursors leads to reduced cell num-
bers, severe attenuation of cells progressing through -selection to
theDP stage, and, in some conditions, diversion of T cell precursors
to a myeloid fate (11, 16, 17, 19). Examples are shown in Fig. 1 A
and B, where bicistronic retroviral vector (LZRS) was used to
transduce PU.1 into T cell precursors from embryonic day (E)-14.5
fetal thymus. Using the coexpressed GFP marker to track vector
expression and CD45 to distinguish lymphoid precursors, subse-
quent development of the transduced cells could be tested by
coculture with OP9-DL1 stromal cells, which promote T cell
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development by presenting theDelta familyNotch ligandDL1 (20).
In this system, as in our previous reports using a fetal thymus organ
culture system (11, 19), PU.1 blocks the development of CD4
CD8 DP cells and greatly enhances the appearance of cells with
the myeloid marker Mac-1 (Fig. 1 A and B). Fig. 5, which is
published as supporting information on the PNAS web site, shows
that PU.1 blocks at the DN3 stage and does not divert the cells to
B or natural killer fates.
The relationship between the myeloid-like cell generation and T
cell developmental arrest effects of PU.1 could be either selective
(Fig. 1D) or directive (Fig. 1E). Selective emergence ofMac-1 cells
could result if PU.1 generally inhibited T lineage cell viability or
proliferation before or during -selection (Fig. 1D, ‘‘attenuation’’).
Alternatively, it could result from diversion of immature T lineage
cells to a nonlymphoid fate (Fig. 1E), emptying the T cell precursor
pool as a byproduct. In the first case, PU.1 levels might not have a
direct causal relationship to lymphocyte developmental plasticity,
whereas the second case would support a role of PU.1 as a major
endogenous regulator of lineage plasticity in pro-T cells. We
therefore tested the effect of forcing PU.1 expression in precursors
with two kinds of transgenes that are expected to preserve pro-T
cell viability and differentiation in different ways: (i) a TCR
transgene that bypasses the requirement for TCR gene rearrange-
ment for -selection and (ii) a Bcl2 transgene.
Fig. 2 and also Fig. 6, which is published as supporting informa-
tion on the PNAS web site, show that E14.5 fetal thymocytes from
mice with the DO11.10 TCR transgene are not protected from the
effects of PU.1 overexpression as measured after 3–5 days of
differentiation onOP9-DL1 cells. TCR transgenic fetal thymocytes
transduced with an empty vector (LZRS, Fig. 2A) or a vector
encoding a non-DNA-binding mutant of PU.1 (215m, Fig. 2B) (11,
16) were overwhelmingly Thy-1 and Mac-1, and60% success-
fully passed through-selection toDN4 or later stage (compare key
to stages in Fig. 2D; ‘‘TCR transgenic total’’ in Fig. 2E). In contrast,
TCR transgenic cells transduced with a vector encoding WT PU.1
Fig. 1. Effects of PU.1 on normal fetal thymus pro-T cell development in
OP9-DL1 culture. (A) Transduction with PU.1 (PU.1 GFP) inhibits generation of
CD4 CD8 DP cells as compared with empty vector control transductants (LZRS
GFP) or nontransduced cells (GFP). (B) Greatly increased percentage of Mac-1
cells in PU.1-transduced GFP cells in OP9-DL1 culture (y axis) as compared with
empty vector (LZRS) GFP transductants or nontransduced GFP cells. Results for
two different transduction conditions are shown. (C) Scheme of normal early T
cell development up to the DP stage. Cells beyond the-selection checkpoint and
 cells (not shown) are pre-T cells. (D and E) Two models for possible modes of
interference with T cell development by PU.1.
Fig. 2. Expression of a rearranged TCR transgene does not protect pro-T cells
from PU.1 effects in OP9-DL1 culture. (A–C) Transduction of PU.1 into total
E14.5 TCR transgenic thymocytes reduces cellularity (green numbers, Left),
enhances the production of Thy-1 Mac-1 cells (red arrow and red numbers,
Center), and blocks appearance of DN4-stage and later cells (red arrow and red
numbers, Right) after 3 days in OP9-DL1 culture. Effects of PU.1 (C) compared
with vector (A) and non-DNA-binding PU.1 mutant (B) controls are shown. (D)
Schematics showing stages corresponding with staining phenotypes in A–C.
The CD44CD25 phenotype corresponding to passage through -selection
and -selection, DN4, is highlighted in blue. (E) PU.1 retards progression from
pre--selection (DN3) to postselection stages (DN4* indicates DN4 to DP
stages) in 4-day OP9-DL1 culture, whether from TCR transgenic thymocytes or
from equivalent WT cells (details are shown in Fig. 6). Results for PU.1-
transduced GFP cells are highlighted in yellow.
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(Fig. 2C) showed a10-times reduction in transduced cell recovery
within 3 days (GFP CD45 cells, green numbers). Note that this
PU.1 vector gives equivalent or higher initial transduction frequen-
cies than the LZRS control (Fig. 7, which is published as supporting
information on the PNAS web site). Losses of GFP cells occurred
throughout the DN stages with particularly sharp depletion from
the DN4 and later stages (red arrow in Fig. 2C Right). Despite the
TCR transgene, which remained prominently expressed on the
surface of most of the surviving PU.1-transduced cells (Fig. 6A), a
substantial population of Thy-1 Mac-1 cells was also generated
(red arrow, red numbers in Fig. 2B Center). These effects closely
resemble those of PU.1 in nontransgenic cells (Fig. 5). The inability
of cell-surface TCR expression to protect against PU.1-mediated
inhibition was confirmed by purifying cohorts of WT or TCR
transgenic thymocytes from stages before or after TCR expression
and comparing their kinetics of differentiation after PU.1 trans-
duction (Fig. 6B–D andFig. 2E).TCR transgenicDN12 cells were
as severely inhibited asWTDN12 cells. Evenmore advancedTCR
transgenic cells that were already expressing cell-surface TCR-
before transduction were blocked in development to DP cells (Fig.
6D). Thus, high-level PU.1 inhibits T lineage development through
some regulatory mechanism other than TCR gene rearrangement.
A Bcl2 Transgene Protects T Cell Development During Constitutive
PU.1 Expression in the Context of NotchDelta Signaling. The effect
of a constitutively expressed Bcl2 transgene showed that PU.1
inhibits pro-T cells through an attenuationmechanism (Fig. 1D). In
striking contrast to the results with normal or TCR transgenic
thymocytes (Figs. 1 and 2) (11, 19), Bcl2 transgenic fetal thymocytes
were protected from PU.1 effects on viability (Fig. 3B). Bcl2
expression promoted high recovery of PU.1-transduced cells from
all subsets of E15.5–16.5 thymocytes, spanning the developmental
range from primitive (Thy-1low, mostly DN1) to pro-T (Thy-1
CD25, DN23) to pre-T (post--selection or -selection, Thy-1
CD25). Protected by the Bcl2 transgene, PU.1-transduced thy-
mocytes could even generate some DP cells in OP9-DL1 culture as
well (Fig. 3D; see also Fig. 8 C and D, which is published as
supporting information on the PNASweb site). The Bcl2 transgene
does not remove normal signaling requirements for development,
however; DP cell generation still depended on the presence of the
Notch ligand DL1, with or without PU.1 (Fig. 3D, ‘‘unsorted’’).
These results imply that for normal fetal thymocytes in OP9-DL1
culture, overexpression of PU.1 attenuates viability andor prolif-
eration of the T lineage cells through a mechanism that can be
counteracted in large part by guaranteeing expression of Bcl2.
The ability of Bcl2 to keep virtually all PU.1-transduced thymo-
cytes alive made it possible to address rigorously the question of
how and whether PU.1 instructs lineage choice of early thymocytes
(Fig. 1E). If PU.1 only promoted outgrowth of Mac-1 cells due to
preferential death of T lineage cells, then Bcl2 transgenic thymo-
cytes, which do not die, should yield a greatly reduced percentage
of Mac-1 cells when forced to express PU.1; however, this is not
what occurs. Within the first day of transduction with PU.1, a shift
to increased Mac-1 expression was already visible in the pro-T
(Thy-1 CD25) fraction of Bcl2 transgenic thymocytes (Fig. 7A,
red arrows), even though pro-T cell survival was not affected. The
Fig. 3. PU.1 effects on Bcl2 transgenic fetal thymocytes: enhanced survival and NotchDelta-dependent regulation of developmental choice. (A) Experimental
scheme for PU.1 effects on subsets of Bcl2 transgenic thymocytes. ON, overnight; LZ, empty vector. (B) Effect of the Bcl2 transgene on recovery of
PU.1-transduced cells: ratios of GFP cell recovery at indicated time points in PU.1-transduced vs. control-transduced cells. Representative data were pooled from
four experiments with E14.5–16.5 fetal thymocytes from B6D2 F2 (WT) and Bcl2 transgenic (Bcl2) embryos. Day 1 indicates WT transductants before OP9 culture
(compare Fig. 7). (C and D) Effects of PU.1 on total Mac-1 cell generation (C) and DP cell generation (D) by Bcl2 transgenic thymocytes in OP9-DL1 culture (dark
blue and purple bars) or OP9 control culture (aqua and yellow bars). Additional results and conditions are shown in Fig. 8. (E–G) Representative data showing
Mac-1 cell differentiation induced by PU.1 from the indicated thymocyte subsets in the presence (Upper) or absence (Lower) of DL1. (E) E15.5 Thy-1low. (F) E16.5
Thy-1 CD25. (G) E16.5 Thy-1 CD25. Red numbers show the percentages of Mac-1 Thy-1 and Mac-1 Thy-1 cells.














developmental shifts caused by PU.1 in the absence of cell death
were at least as pronounced as in WT cells (Fig. 7B). As described
below, PU.1 induced Mac-1 cells to develop from Bcl2 transgenic
thymocytes but only under specific conditions. This system pro-
vided robust and stable PU.1 expression in the transductants as
shown below, enabling the other conditions needed for lineage
diversion to be dissected.
NotchDelta Signaling Constrains PU.1-Induced Mac-1 Expression on
Thy-1 Fetal Thymocytes. Fig. 3C reveals that contact of PU.1-
transduced thymocytes with DL1 has a dramatic, specific, and
reproducible effect on their ability to generateMac-1 cells (yellow
vs. purple bars). PU.1 overexpression in normal thymocytes inhibits
survival on OP9 control as well as on OP9-DL1 stroma (Fig. 5), but
the Bcl2 transgene enables PU.1-transduced cells to survive almost
as well as controls in both conditions (Fig. 8A, yellow vs. aqua bars).
Fig. 3 E–G Lower shows that PU.1 could induce prolific Mac-1
cell-surface expression in majorities of primitive Thy-1low cells,
pro-T cells, and even pre-T cells, provided that the cells were
maintained in OP9 control culture without DL1 (Fig. 3C, yellow
bars). These Mac-1 cells were large and expressed CD11c, F480,
and, in some cases, macrophage colony-stimulating factor receptor,
but not Gr-1 (Fig. 9A, which is published as supporting information
on the PNAS web site). The Mac-1 cells emerging from pro- and
pre-T cells were all initially Thy-1 (Fig. 9 and data not shown).
Then, many of those emerging from pro-T cells (Fig. 3F), although
not from pre-T cells (Fig. 3G), down-regulated Thy-1 expression
between days 3 and 5 on OP9. Importantly, PU.1-transduced
Mac-1 cells activated a broad spectrum of myeloid genes while
they were still Thy-1 and continued to express appreciable CD3
and CD3RNA (Fig. 9 B and C). In contrast, the same transduced
Thy-1 cells did not generate aMac-1 population at all if cultured
on OP9-DL1 instead (Fig. 3 F and G Upper and C, purple bars).
Absolute numbers as well as percentages of Mac-1 cells were
dramatically reduced. Thus, the presence of the NotchDelta signal
blocked activation of the myeloid program and down-regulation of
Thy-1 in these cells.
This effect of NotchDelta signaling was developmentally spe-
cific, for in primitive cells that were still Thy-1 when transduced
(Fig. 3E), the effect was much weaker or absent. These primitive
cells were not committed myeloid precursors, because they devel-
oped quickly into T lineage progeny on OP9-DL1 stroma (90%)
(Fig. 3E Upper Left). But when transduced with PU.1, these cells
generated profuse myeloid-like Thy-1 Mac-1 cells with similar
efficiency in either OP9-DL1 or OP9 control culture (Fig. 3E Right
and C). The response of this primitive subset of fetal thymocytes
presumably accounts for the Mac-1 cells generated when bulk
populations of PU.1-transduced thymocytes are cultured on OP9-
DL1 (Figs. 1B and 2C).
The results in Fig. 3were robust in diverse culture conditionswith
thymocyte subsets from E15.5 or E16.5 (Fig. 8B). Thus, once
initiated, the T lineage specification process marked by expression
of Thy-1 brings themyeloid diversion activity of PU.1 under control
of a veto from NotchDelta signaling.
NotchDelta Signaling as a Specific Modifier of PU.1 Actions on Target
Genes.Todefine themolecularmechanism throughwhichPU.1 and
Notch compete for lineage specification of pro-T cells, we analyzed
the earliest gene expression changes induced in fetal thymocytes in
response to PU.1 transduction with andwithout the rescuing effects
of NotchDelta signaling. We sought three kinds of system com-
ponents in an attempt to determine the components that are most
likely to be central to a lineage control switch: (i) gene expression
effects that might explain T lineage attenuation by PU.1, (ii) the
earliest myeloid-associated responses, and (iii) identification of the
responses most highly sensitive to NotchDelta signaling. We
therefore monitored known pro-T cell differentiation genes in-
volved in pre-TCR assembly and signaling, Notch target genes, and
known essential T lineage regulatory genes (reviewed in refs.
21–24) as well as myeloid marker and regulatory genes.
Fig. 4 shows effects of PU.1 on gene expression inBcl2 transgenic
cells that were transduced overnight and then returned to culture
on either OP9-DL1 or OP9 control stroma for an additional day
before preparatively sorting the GFP Thy-1 transductants (Fig.
4B). The major effects seen at 40 h (Fig. 4A) actually begin within
the first 20 h after transduction, and all depend on the integrity of
the PU.1DNA-binding domain (Fig. 10A andB, which is published
as supporting information on the PNASweb site). Because baseline
gene expression changes substantially between the DN1 and DN4
stages (2, 12, 25, 26), pro-T regulatory genes, including Notch 1,
Notch 3, and others, were also analyzed separately in control and
PU.1-transducedThy-1low, pro-T, and pre-T cells (Fig. 10C). Except
as noted, gene-specific effects of PU.1 were similar across subsets.
The basis of attenuation and -selection blockade was obvious.
PU.1 overexpression (Fig. 4A, far left) inhibited expression of
known essential T lineage regulators, including TCF-1 (T cell factor
1), Ets1, Ets2, Gfi1 (growth factor independence 1), Myb, and E
protein genes E2A andHEB, as well as expression of Rag-1 and the
crucial signaling molecules Zap70, Lck, and LAT (linker for
activation of T cells) (Fig. 4A). Weaker but still significant effects
were seen on FOG-1 (friend of GATA 1), CD3 and , and Ikaros
(in the Thy-1 subsets only; Fig. 10C). Response specificity is shown
by the minimal changes in other pro-T cell genes (e.g., Runx3,
Runx1, and GATA-3).
The negative effects on pro-T cell genes preceded significant
effects on most myeloid genes, but Mac-1, macrophage colony-
stimulating factor receptor, and, at a low level, endogenous PU.1
itself were induced. Also induced were myeloid-compatible regu-
latory genes Id2, Egr2, and Bcl11a (Fig. 4A and Fig. 11, which is
published as supporting information on the PNAS web site).
However, at this time point, PU.1 caused little if any up-regulation
of the myeloid-driving transcription factors of the CEBP family
(15, 27); they remained at very low levels (Fig. 4A) and were mostly
affected by the presence or absence of NotchDL1 signaling.
Notch 1, Notch 3, and Notch signal delivery were all unaffected
by PU.1 in these Thy-1 cells (Figs. 4A and 10B). Notch targets
HES-1 (hairy enhancer of split 1), Deltex1, and pT were all
remarkably sensitive to the presence or absence of DL1 (Fig. 4A,
baseline vs. yellow bars and red vs. black bars), butDeltex1 and pT
were virtually indifferent to the addition of PU.1 (Fig. 4A, baseline
vs. red bars and black bars vs. yellow bars; Fig. 4C, group 3). HES-1
was sensitive to PU.1 as well as dependent on DL1 (Fig. 4A),
indicating more complex regulation. Thus, in Thy-1 cells, PU.1
and Notch signaling can provide independent regulatory inputs.
However, this important feature did not hold in Thy-1low cells,
where PU.1 also down-regulated Notch 1 and Notch 3 (Fig. 10C).
The gene expression effects of PU.1 in general were blunted
by NotchDL1 signaling (Fig. 4A, red vs. purple bars). However,
different genes fell into distinct patterns of response to PU.1 
DL1, as summarized in Fig. 4C (P values are given in Table 1,
which is published as supporting information on the PNAS web
site). The positive regulatory effects of PU.1 on macrophage
colony-stimulating factor receptor, endogenous PU.1, Bcl11a,
and Egr2 were least affected, and even Mac-1 was strongly
induced in the presence of DL1 (Figs. 4C, group 1, and 11). DL1
protected most pro-T cell genes from maximal inhibition, but
many were still significantly down-regulated by PU.1 in the
presence of DL1 (Fig. 4C, group 2). These genes included Rag-1,
several signaling genes, and TCF-1 as described above, and also
the Ets family factor Ets1, Bcl11b, and the GATA-3 interaction
partner FOG-1 (2, 24) (Fig. 11).
The genes showing themost dramatic influences of NotchDelta
signaling on the response to PU.1 were almost entirely pro-T cell
regulatory genes (Fig. 4C, groups 4–6). One set was repressed by
PU.1 and also dependent on DL1, with additive (logarithmic scale)
down-regulation when PU.1 and loss of DL1 were combined (Fig.
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4C, group 6). These genes includeHES-1,Ets2, the alternativeHEB
isoform HEBAlt, and, to a weaker overall extent, E2A. More
extreme relationships between Notch and PU.1 effects were shown
by c-Myb, Gfi1, and Id2 (Fig. 4C, groups 4 and 5). These genes were
minimally affected by PU.1 in the presence of DL1 or by removal
of DL1 alone but could be substantially repressed (c-Myb andGfi1)
or activated (Id2) by PU.1 if and only if DL1 was absent. DL1 also
blocked the weaker repression of Ikaros and canonical-form HEB
by PU.1. Thus, although Notch signaling did not appear to regulate
Id2 or c-Myb directly, it exerted profound control over the ability
of PU.1 to activate Id2 (Fig. 4C, group 4) or repress c-Myb andGfi1
(Fig. 4C, group 5) and perhaps others. These genes are thus
identified as particularly interesting candidates for controllers of the
diversion response.
Discussion
Developmental plasticity is sustained throughout early T cell dif-
ferentiation in the thymus, as shown when differentiating pro-T
cells are removed from the thymic microenvironment. Here, we
show that environmental NotchDelta signaling can be a major
lineage fidelity factor for pro-T cells fromT lineage specification up
to TCR-dependent selection by selectively preventing PU.1 from
exerting a subset of its transcriptional activities even when, in other
respects, PU.1 activity remains intact. This Notch activity is seen
long after Notch signaling blocks B cell development and starts the
T lineage specification process. NotchDelta interaction is remark-
ably powerful at preventing diversion, even when PU.1 is forcibly
expressed in pro-T cells at levels that significantly hamper prolif-
eration and developmental progression within the T lineage. Our
results show that PU.1 effects on a variety of regulatory and
signaling genes may contribute to the developmental arrest in
response to forced PU.1 expression in the presence or absence of
Notch signaling. However, Notch-dependent protection of overall
E protein activity, c-Myb, and possibly Gfi1 and HES-1 from PU.1
repression is tightly correlated with lineage fidelity, suggesting key
roles for these factors as brakes on a lineage switch.
At high levels, PU.1 should interfere with TCR gene rearrange-
ment through its inhibition of Rag gene expression, and its normal
expression pattern, reciprocal to Rag-1, may constrain the timing of
rearrangement in vivo. The spectrum of gene expression effects of
forced high-level expression of PU.1 is consistent with partial
retrograde differentiation; many of the genes affected would nor-
mally peak in expression during the DN3 stage (2). Multiple
regulatory and signaling genes are down-regulated by PU.1, most
evenwhenDL1 is present, and these effects undoubtedly contribute
to population attenuation. However, in the presence of DL1, all
Fig. 4. Effects of PU.1 on gene expression in pro-T cells: selective modulation by NotchDelta signaling. (A) Effects of PU.1 on gene expression in Thy-1 cells
after 40 h of transduction in the presence or absence of NotchDelta signaling. Means  SEM of log10-transformed data from three independent experiments
are shown normalized to levels in empty vector controls in OP9-DL1 culture. For each gene, (DL  LZ)  log1  0. Red bars, PU.1-transduced, OP9-DL1 culture;
yellow bars, empty vector-transduced, OP9 control culture; purple bars, PU.1-transduced, OP9 control culture. In the gene list, ‘‘PU.1 endog’’ is endogenous PU.1
(3 untranslated). ‘‘PU.1 coding’’ includes exogenous. (B) Generation of samples for A. (C) Schematic of inferred topologies of regulatory inputs for six groups
of pro-T cell genes. Genes that are weakly affected are shown in parentheses. In group 1, only Mac-1 is sensitive to DL1 (other genes are shown in Fig. 11). Genes
not shown may fall between categories. See text for details.














these effects are leaky, as shown by the ability to rescue with Bcl2.
Also, cells can survive all these effects and return to normal
differentiation if they express PU.1 only transiently (Fig. 8D) (11).
The reversibility, stage dependence, and environmental sensitivity
of PU.1 effects probably represent the reasons that PU.1 can be
successfully harnessed for a role in normal pro-T cell development.
NotchDelta signaling protects pro-T cells through target gene-
specific modulation of PU.1 activities. There is a blunting of PU.1
effects generally, and repressive effects especially. However, genes
such as c-Myb, Gfi1, and Id2 stand out for their switch-like,
Notch-dependent logical processing of inputs from PU.1. Such
regulatory genes, and possibly the pro-T genes Ets2, HES-1, Ikaros,
and HEBAlt as well, are the best of the candidates tested for
participants in a lineage switch. All-or-none control of lineage
diversion by PU.1 is also found in a clonal pro-T cell line model
system, where strong effects on c-Myb, HEBAlt, and Id2 also are
seen (16).
Net activities of basic helix–loop–helix (bHLH) E proteins (E2A
and HEB) and their antagonist Id2 seem to be particularly tightly
correlated with lineage fidelity when considered as a group rather
than individually. The effective level of bHLHactivity in developing
lymphocytes is normally titrated through shifting Id:E protein
balances (28). It is striking that all of the positively acting E proteins
tested here are significantly repressed by PU.1 when DL1 is absent
and that only thendoes PU.1 activate their collective antagonist Id2.
The effect overall should be multiplicative: a large cumulative
decrease in bHLH activity caused by PU.1, specifically when
NotchDL1 signaling is absent. This E protein inhibition could
contribute directly to the myeloid or dendritic cell potential of the
cells (29, 30). Our evidence that Notch signaling positively regulates
bHLH activity in pro-T cells could also explain Notch effects on T
vs. natural killer cell development (31, 32).
In summary, PU.1 serves as a probe to discern underlying
developmental transitions in pro-T cell regulatory biology that
control their lineage plasticity. Once cells pass through initial T
lineage specification, Notch expression becomes insensitive to PU.1
levels, and the normal role of PU.1 in uncommitted pro-T cells
becomes constrained by NotchDelta signaling effects, which se-
lectively antagonize reprogramming. Furthermore, the results im-
ply a fundamental asymmetry between T and B cell development:
The lineage fidelity role played by the intrinsic, cell-autonomous
transcription factor Pax-5 in B cell development (18, 33) appears to
be ‘‘outsourced’’ to an environmental signaling mechanism
throughout the early stages of T cell development. Thus, the thymus
is not only important for inducing the T cell differentiation program
and for nurturing developing T cells through growth and viability
functions (23), but thymic Notch ligands also protect T cell devel-
opment from the regulatory hazard of the stemprogenitor cell
factors it depends on in its early stages, such as PU.1.
Materials and Methods
For detailed methods, see Supporting Methods, which is published
as supporting information on the PNAS web site.
Mice. C57BL6 (B6) and E-Bcl2–25 (Bcl2-tg) mice were from our
colony (16). Normal B6D2 F2 embryos were obtained from the
California Institute of Technology Genetically Engineered Mouse
Service (11). For Bcl2-tg or TCR-tg fetal thymocytes, homozygous
Bcl2-tg or TCR transgenic DO-11.10 mice from The Jackson
Laboratory (Bar Harbor, ME) were mated with B6 mice.
Transduction of Cells.Non-tissue culture-treated plates were coated
with RetroNectin (24 gml) and then with retroviral stocks
described in refs. 11 and 16 (the same stocks were used for all
experiments). Cells were then incubated on the coated plates for
4–20 h inOP9 culturemediumwith 0.1mM2-mercaptoethanol and
also IL-7 and Flt3L or stem cell factor at 5 ngml each. For variant
conditions, see Figs. 7 and 8.
OP9-DL1 Cultures.Lymphocyte differentiation cultures onOP9-DL1
and OP9 control stroma are described in detail in refs. 12 and 34.
Differentiation cultures always contained Flt3L and IL-7.
Cell Staining and Flow Cytometry. Cell staining methods and anti-
bodies were as reported in refs. 12, 26, and 34, except that CD45
staining was used together with GFP detection to gate all analyses
of transduced thymocytes from OP9 cultures. For details, see
Supporting Methods.
Gene Expression Analysis. Quantitative real-time RT-PCR analysis
was carried out as described in refs. 2, 12, 16, and 26 with
modifications and using primers described in Supporting Methods.
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